Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?

[1]  S. Demeret,et al.  Postallogeneic transplantation progressive multifocal leukoencephalopathy successfully treated by nivolumab , 2019, British journal of haematology.

[2]  C. Mengelle,et al.  Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy , 2019, Emerging infectious diseases.

[3]  A. Straube,et al.  Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[4]  Bryan R. Smith,et al.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy , 2019, The New England journal of medicine.

[5]  C. Mengelle,et al.  Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab. , 2019, The New England journal of medicine.

[6]  A. Paetau,et al.  The Incidence and Predisposing Factors of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy in Southern Finland: A Population-Based Study , 2019, Open forum infectious diseases.

[7]  A. Verma,et al.  Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant – a case series , 2018, Leukemia & lymphoma.

[8]  J. Ramon,et al.  Authors and Affiliations , 2014 .

[9]  J. Sejvar,et al.  PML diagnostic criteria , 2013, Neurology.

[10]  David Green,et al.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.

[11]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.